Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24672114,relative bioavailabilities,"The mean (SD) relative bioavailabilities, as represented by AUC0-∞, of amlodipine and benazeprilat for tablets versus capsules were 1.060 (0.170) versus 0.949 (0.197), respectively.","Bioavailability study of fixed-dose tablet versus capsule formulation of amlodipine plus benazepril: A randomized, single-dose, two-sequence, two-period, open-label, crossover study in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24672114/),,1.060,19576,DB00542,Benazepril
,24672114,relative bioavailabilities,"The mean (SD) relative bioavailabilities, as represented by AUC0-∞, of amlodipine and benazeprilat for tablets versus capsules were 1.060 (0.170) versus 0.949 (0.197), respectively.","Bioavailability study of fixed-dose tablet versus capsule formulation of amlodipine plus benazepril: A randomized, single-dose, two-sequence, two-period, open-label, crossover study in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24672114/),,0.949,19577,DB00542,Benazepril
,21953651,flow rate,"After solid-phase extraction, chromatography was performed on a Luna(®) RP-C(18) (2) column with methanol-water-formic acid (65:35:1, v/v/v) as mobile phase and a flow rate of 0.4 mL/min.",Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953651/),[ml] / [min],0.4,33669,DB00542,Benazepril
,21953651,m/z transitions,"The MS was set to positive-mode electrospray ionization and multiple reaction monitoring, analyzing the m/z transitions channels 377.3 → 234.2, 349.3 → 206.1 and 425.3 → 351.2 for enalapril, enalaprilat and IS.",Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953651/),,377.3,33670,DB00542,Benazepril
,21953651,m/z transitions,"The MS was set to positive-mode electrospray ionization and multiple reaction monitoring, analyzing the m/z transitions channels 377.3 → 234.2, 349.3 → 206.1 and 425.3 → 351.2 for enalapril, enalaprilat and IS.",Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953651/),,234.2,33671,DB00542,Benazepril
,21953651,m/z transitions,"The MS was set to positive-mode electrospray ionization and multiple reaction monitoring, analyzing the m/z transitions channels 377.3 → 234.2, 349.3 → 206.1 and 425.3 → 351.2 for enalapril, enalaprilat and IS.",Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953651/),,349.3,33672,DB00542,Benazepril
,21953651,m/z transitions,"The MS was set to positive-mode electrospray ionization and multiple reaction monitoring, analyzing the m/z transitions channels 377.3 → 234.2, 349.3 → 206.1 and 425.3 → 351.2 for enalapril, enalaprilat and IS.",Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953651/),,206.1,33673,DB00542,Benazepril
,21953651,m/z transitions,"The MS was set to positive-mode electrospray ionization and multiple reaction monitoring, analyzing the m/z transitions channels 377.3 → 234.2, 349.3 → 206.1 and 425.3 → 351.2 for enalapril, enalaprilat and IS.",Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21953651/),,425.3,33674,DB00542,Benazepril
,8359184,maximum plasma concentration,The maximum plasma concentration of benazepril was found between 0.5 and 2 h after dosing (median 1 h).,Pharmacokinetics and pharmacodynamics of benazepril hydrochloride in patients with major proteinuria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359184/),h,0.5 and 2,66472,DB00542,Benazepril
,8359184,initial,"The elimination of benazeprilat from plasma was biphasic, with mean initial and terminal half-lives of 3.0 and 17.3 h, respectively.",Pharmacokinetics and pharmacodynamics of benazepril hydrochloride in patients with major proteinuria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359184/),h,3.0,66473,DB00542,Benazepril
,8359184,terminal half-lives,"The elimination of benazeprilat from plasma was biphasic, with mean initial and terminal half-lives of 3.0 and 17.3 h, respectively.",Pharmacokinetics and pharmacodynamics of benazepril hydrochloride in patients with major proteinuria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359184/),h,17.3,66474,DB00542,Benazepril
,9293618,tmax,2. Benazepril appeared quickly in the plasma (tmax 0.5 h) and was rapidly eliminated by metabolism to benazeprilat.,"Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9293618/),h,0.5,72119,DB00542,Benazepril
,9293618,tmax,Peak benazeprilat concentrations were attained later (tmax 1.25 h) and declined biphasically with a rapid elimination phase (t1/2 lambda 1 1.1 and 1.7 h after single and the last repeated dose respectively) followed by a terminal elimination phase (t1/2 lambda z 11.7 and 19.0 h after single and repeated dose respectively).,"Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9293618/),h,1.25,72120,DB00542,Benazepril
,9293618,t1/2 lambda 1,Peak benazeprilat concentrations were attained later (tmax 1.25 h) and declined biphasically with a rapid elimination phase (t1/2 lambda 1 1.1 and 1.7 h after single and the last repeated dose respectively) followed by a terminal elimination phase (t1/2 lambda z 11.7 and 19.0 h after single and repeated dose respectively).,"Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9293618/),h,1.1,72121,DB00542,Benazepril
,9293618,t1/2 lambda 1,Peak benazeprilat concentrations were attained later (tmax 1.25 h) and declined biphasically with a rapid elimination phase (t1/2 lambda 1 1.1 and 1.7 h after single and the last repeated dose respectively) followed by a terminal elimination phase (t1/2 lambda z 11.7 and 19.0 h after single and repeated dose respectively).,"Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9293618/),h,1.7,72122,DB00542,Benazepril
,9293618,t1/2 lambda z,Peak benazeprilat concentrations were attained later (tmax 1.25 h) and declined biphasically with a rapid elimination phase (t1/2 lambda 1 1.1 and 1.7 h after single and the last repeated dose respectively) followed by a terminal elimination phase (t1/2 lambda z 11.7 and 19.0 h after single and repeated dose respectively).,"Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9293618/),h,11.7,72123,DB00542,Benazepril
,9293618,t1/2 lambda z,Peak benazeprilat concentrations were attained later (tmax 1.25 h) and declined biphasically with a rapid elimination phase (t1/2 lambda 1 1.1 and 1.7 h after single and the last repeated dose respectively) followed by a terminal elimination phase (t1/2 lambda z 11.7 and 19.0 h after single and repeated dose respectively).,"Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9293618/),h,19.0,72124,DB00542,Benazepril
,9293618,mean residence time,The mean residence time for benazeprilat was 15.2 h after the single dose and 17.4 h after the 14th dose.,"Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9293618/),h,15.2,72125,DB00542,Benazepril
,9293618,mean residence time,The mean residence time for benazeprilat was 15.2 h after the single dose and 17.4 h after the 14th dose.,"Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9293618/),h,17.4,72126,DB00542,Benazepril
,9293618,ratio of AUC[0-->24 h]'s,"3. Repeated administration of benazepril produced moderate bioaccumulation of benazeprilat; the ratio of AUC[0-->24 h]'s after the 14th dose as compared with the single dose was 1.47, equivalent to a half-life for accumulation (t1/2acc) of 14.6 h.","Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9293618/),,1.47,72127,DB00542,Benazepril
,9293618,half-life for accumulation (t1/2acc),"3. Repeated administration of benazepril produced moderate bioaccumulation of benazeprilat; the ratio of AUC[0-->24 h]'s after the 14th dose as compared with the single dose was 1.47, equivalent to a half-life for accumulation (t1/2acc) of 14.6 h.","Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9293618/),h,14.6,72128,DB00542,Benazepril
,9293618,Emax,"After both single doses and at steady-state, benazepril produced inhibition of ACE activity in all dogs that was maximal at peak effect (Emax = 100%) and long-lasting (> 85% inhibition was present at 24 h).","Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9293618/),%,100,72129,DB00542,Benazepril
,20629042,flow rate,"The reconstituted samples were chromatographed on C(18) column by pumping 0.1% formic acid-acetonitrile (15:85, v/v) at a flow rate of 1 mL/min.","Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20629042/),[ml] / [min],1,77437,DB00542,Benazepril
,20629042,run time,A run time of 2.5 min for each sample made it possible to analyze more than 400 human plasma samples per day.,"Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20629042/),min,2.5,77438,DB00542,Benazepril
,15639452,m/,"The quantification of target compounds was using a selective ionization recording at m/z 425.5 for benazepril, m/z 397.5 for benzeprilat and m/z 288.3 for rutaecarpine.",Simultaneous determination of benazepril hydrochloride and benazeprilat in plasma by high-performance liquid chromatography/electrospray-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15639452/),,425.5,78531,DB00542,Benazepril
,15639452,m/z,"The quantification of target compounds was using a selective ionization recording at m/z 425.5 for benazepril, m/z 397.5 for benzeprilat and m/z 288.3 for rutaecarpine.",Simultaneous determination of benazepril hydrochloride and benazeprilat in plasma by high-performance liquid chromatography/electrospray-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15639452/),,397.5,78532,DB00542,Benazepril
,8008712,Tmax,BZPH was absorbed rapidly into the bloodstream (Tmax = 0.5 hr after ORAL).,Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008712/),h,0.5,79788,DB00542,Benazepril
,8008712,half-life,"Absorption was also rapid for SI, with a postinfusion half-life (0.57 hr) nearly identical to that for ORAL (0.59 hr).",Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008712/),h,0.57,79789,DB00542,Benazepril
,8008712,half-life,"Absorption was also rapid for SI, with a postinfusion half-life (0.57 hr) nearly identical to that for ORAL (0.59 hr).",Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008712/),h,0.59,79790,DB00542,Benazepril
,8008712,apparent half-life,"The absorption rate after COLON was much slower (lower Cmax and longer Tmax) compared to that after SI, and the apparent half-life (1.7 hr) was prolonged.",Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008712/),h,1.7,79791,DB00542,Benazepril
,8008712,AUC ratios,"The metabolite-to-drug AUC ratios were comparable for SI and ORAL (8.9 vs 9.7), indicating that first-pass metabolism of BZPH was neither saturable nor input rate dependent.",Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008712/),,8.9,79792,DB00542,Benazepril
,8008712,AUC ratios,"The metabolite-to-drug AUC ratios were comparable for SI and ORAL (8.9 vs 9.7), indicating that first-pass metabolism of BZPH was neither saturable nor input rate dependent.",Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008712/),,9.7,79793,DB00542,Benazepril
,8008712,AUC ratio,"The metabolite-to-drug AUC ratio was reduced for COLON (5.0), indicating that the mechanism of absorption of BZPH in the colon may be different than that after SI and ORAL.",Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008712/),,5.0,79794,DB00542,Benazepril
,28371693,Systemic bioavailability,Systemic bioavailability of benazeprilat after PO benazepril was 3-4%.,Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371693/),%,3-4,85230,DB00542,Benazepril
,28371693,Maximum ACE inhibitions,"Maximum ACE inhibitions from baseline were 99.63% (IV benazepril), 6.77% (placebo) and 78.91%, 85.74% and 89.51% (for the three PO benazepril doses).",Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371693/),%,99.63,85231,DB00542,Benazepril
,28371693,Maximum ACE inhibitions,"Maximum ACE inhibitions from baseline were 99.63% (IV benazepril), 6.77% (placebo) and 78.91%, 85.74% and 89.51% (for the three PO benazepril doses).",Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371693/),%,6.77,85232,DB00542,Benazepril
,28371693,Maximum ACE inhibitions,"Maximum ACE inhibitions from baseline were 99.63% (IV benazepril), 6.77% (placebo) and 78.91%, 85.74% and 89.51% (for the three PO benazepril doses).",Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371693/),%,78.91,85233,DB00542,Benazepril
,28371693,Maximum ACE inhibitions,"Maximum ACE inhibitions from baseline were 99.63% (IV benazepril), 6.77% (placebo) and 78.91%, 85.74% and 89.51% (for the three PO benazepril doses).",Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371693/),%,85.74,85234,DB00542,Benazepril
,28371693,Maximum ACE inhibitions,"Maximum ACE inhibitions from baseline were 99.63% (IV benazepril), 6.77% (placebo) and 78.91%, 85.74% and 89.51% (for the three PO benazepril doses).",Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28371693/),%,89.51,85235,DB00542,Benazepril
,2271751,time to reach maximum concentration,"However, the time to reach maximum concentration (0.5 h) was not affected.",The influence of hepatic cirrhosis on the pharmacokinetics of benazepril hydrochloride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271751/),h,0.5,92846,DB00542,Benazepril
,2271751,time to maximum concentration,The plasma kinetics and the urinary excretion of the metabolite benazeprilat were not significantly altered: Area under the curve and maximum concentration as well as time to maximum concentration (1.5 h) were comparable with those in the healthy subjects.,The influence of hepatic cirrhosis on the pharmacokinetics of benazepril hydrochloride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271751/),h,1.5,92847,DB00542,Benazepril
,1279278,time to peak (Tmax),"The time to peak (Tmax) and the apparent elimination half-life (t1/2) for benazepril were 0.6-0.7 h and 0.4-0.8 h, respectively.",Pharmacokinetics and pharmacodynamics of benazepril in hypertensive patients with normal and impaired renal function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1279278/),h,0.6-0.7,98156,DB00542,Benazepril
,1279278,apparent elimination half-life (t1/2),"The time to peak (Tmax) and the apparent elimination half-life (t1/2) for benazepril were 0.6-0.7 h and 0.4-0.8 h, respectively.",Pharmacokinetics and pharmacodynamics of benazepril in hypertensive patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1279278/),h,0.4-0.8,98157,DB00542,Benazepril
,1279278,Tmax,Tmax for its diacid was 1.5-2.4 h in both groups.,Pharmacokinetics and pharmacodynamics of benazepril in hypertensive patients with normal and impaired renal function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1279278/),h,1.5-2.4,98158,DB00542,Benazepril
,10651464,elimination half life (t1/2),"HCl, maximum benazepril concentrations were recorded at the first sample (2 h) and declined relatively rapidly with an elimination half life (t1/2) of 1.4 h.",Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10651464/),h,1.4,104294,DB00542,Benazepril
,10651464,half lives of each phase,Highest benazeprilat concentrations were recorded at the first sample (2 h) in most cats and declined biphasically with half lives of each phase of 2.4 and 27.7 h.,Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10651464/),h,2.4,104295,DB00542,Benazepril
,10651464,half lives of each phase,Highest benazeprilat concentrations were recorded at the first sample (2 h) in most cats and declined biphasically with half lives of each phase of 2.4 and 27.7 h.,Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10651464/),h,27.7,104296,DB00542,Benazepril
,10651464,accumulation ratios (R),"With repeated administration, plasma benazeprilat concentrations accumulated slightly with accumulation ratios (R) of 1.46, 1.36 and 1.24 for the 0.25, 0.5 and 1.0 mg/kg dosages of benazepril.",Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10651464/),,1.46,104297,DB00542,Benazepril
,10651464,accumulation ratios (R),"With repeated administration, plasma benazeprilat concentrations accumulated slightly with accumulation ratios (R) of 1.46, 1.36 and 1.24 for the 0.25, 0.5 and 1.0 mg/kg dosages of benazepril.",Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10651464/),,1.36,104298,DB00542,Benazepril
,10651464,accumulation ratios (R),"With repeated administration, plasma benazeprilat concentrations accumulated slightly with accumulation ratios (R) of 1.46, 1.36 and 1.24 for the 0.25, 0.5 and 1.0 mg/kg dosages of benazepril.",Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10651464/),,1.24,104299,DB00542,Benazepril
> or =,10651464,maximum effect (Emax,"The maximum effect (Emax, % inhibition of ACE as compared to baseline) was > or = 98% after single and 100% with repeated administration.",Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10651464/),%,98,104300,DB00542,Benazepril
,10651464,maximum effect (Emax,"The maximum effect (Emax, % inhibition of ACE as compared to baseline) was > or = 98% after single and 100% with repeated administration.",Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10651464/),%,100,104301,DB00542,Benazepril
,7867683,AUC (0-4 h),"The mean values of AUC (0-4 h), Cmax and Tmax for benazepril given as combination versus given alone were 161 vs 140 ng.h.ml-1, 168 vs 149 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),[h·ng] / [ml],161,105857,DB00542,Benazepril
,7867683,Cmax,"The mean values of AUC (0-4 h), Cmax and Tmax for benazepril given as combination versus given alone were 161 vs 140 ng.h.ml-1, 168 vs 149 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),[h·ng] / [ml],140,105858,DB00542,Benazepril
,7867683,Cmax,"The mean values of AUC (0-4 h), Cmax and Tmax for benazepril given as combination versus given alone were 161 vs 140 ng.h.ml-1, 168 vs 149 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,168,105859,DB00542,Benazepril
,7867683,Cmax,"The mean values of AUC (0-4 h), Cmax and Tmax for benazepril given as combination versus given alone were 161 vs 140 ng.h.ml-1, 168 vs 149 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,149,105860,DB00542,Benazepril
,7867683,Tmax,"The mean values of AUC (0-4 h), Cmax and Tmax for benazepril given as combination versus given alone were 161 vs 140 ng.h.ml-1, 168 vs 149 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,149,105861,DB00542,Benazepril
,7867683,AUC (0-24 h),"The mean values of AUC (0-24 h), Cmax and Tmax for benazeprilat after benazepril given as combination versus given alone were 1470 vs 1410 ng.h.ml-1, 292 vs 257 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),[h·ng] / [ml],1470,105862,DB00542,Benazepril
,7867683,Cmax,"The mean values of AUC (0-24 h), Cmax and Tmax for benazeprilat after benazepril given as combination versus given alone were 1470 vs 1410 ng.h.ml-1, 292 vs 257 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),[h·ng] / [ml],1410,105863,DB00542,Benazepril
,7867683,Cmax,"The mean values of AUC (0-24 h), Cmax and Tmax for benazeprilat after benazepril given as combination versus given alone were 1470 vs 1410 ng.h.ml-1, 292 vs 257 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,292,105864,DB00542,Benazepril
,7867683,Cmax,"The mean values of AUC (0-24 h), Cmax and Tmax for benazeprilat after benazepril given as combination versus given alone were 1470 vs 1410 ng.h.ml-1, 292 vs 257 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,257,105865,DB00542,Benazepril
,7867683,Tmax,"The mean values of AUC (0-24 h), Cmax and Tmax for benazeprilat after benazepril given as combination versus given alone were 1470 vs 1410 ng.h.ml-1, 292 vs 257 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,292,105866,DB00542,Benazepril
,7867683,Tmax,"The mean values of AUC (0-24 h), Cmax and Tmax for benazeprilat after benazepril given as combination versus given alone were 1470 vs 1410 ng.h.ml-1, 292 vs 257 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,257,105867,DB00542,Benazepril
,7867683,AUC (0-144 h),"The mean values of AUC (0-144 h), Cmax and Tmax for amlodipine given as combination versus given alone were 118 vs 114 ng.h.ml-1, 2.5 vs 2.3 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),[h·ng] / [ml],118,105868,DB00542,Benazepril
,7867683,AUC (0-144 h),"The mean values of AUC (0-144 h), Cmax and Tmax for amlodipine given as combination versus given alone were 118 vs 114 ng.h.ml-1, 2.5 vs 2.3 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),[h·ng] / [ml],114,105869,DB00542,Benazepril
,7867683,Cmax,"The mean values of AUC (0-144 h), Cmax and Tmax for amlodipine given as combination versus given alone were 118 vs 114 ng.h.ml-1, 2.5 vs 2.3 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),[h·ng] / [ml],114,105870,DB00542,Benazepril
,7867683,Cmax,"The mean values of AUC (0-144 h), Cmax and Tmax for amlodipine given as combination versus given alone were 118 vs 114 ng.h.ml-1, 2.5 vs 2.3 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,2.5,105871,DB00542,Benazepril
,7867683,Tmax,"The mean values of AUC (0-144 h), Cmax and Tmax for amlodipine given as combination versus given alone were 118 vs 114 ng.h.ml-1, 2.5 vs 2.3 ng.",Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867683/),ng,2.3,105872,DB00542,Benazepril
,16541390,flow rate,The mobile phase consisted of 55% acetonitrile in water containing 0.3% v/v formic acid and pumped at a flow rate of 0.15 ml min(-1).,"Development and validation of a liquid chromatographic/electrospray ionization mass spectrometric method for the determination of benazepril, benazeprilat and hydrochlorothiazide in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16541390/),[ml] / [min],0.15,120959,DB00542,Benazepril
,33352616,recovery,Solid-phase extraction technique employing Waters Oasis SPE cartridges gave clean samples with very high recovery of 97%.,A sensitive and efficient LC-MS/MS method for the bioanalysis of fosinopril diacid from human plasma and its application for a bioequivalence study in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33352616/),%,97,139877,DB00542,Benazepril
,22622066,gradient flow rates,"The mobile phase was composed of 0.1% acetic acid-acetonitrile (50:50, v/v), with gradient flow rates: 0.6 mL/min (0-4.55 min); 4.55-4.65 min, 1 mL/min; 1 mL/min (4.65-9.5 min); 9.5-9.6 min, 0.6 mL/min; 0.6 mL/min (9.6-10 min).","Simultaneous determination of lercanidipine, benazepril and benazeprilat in plasma by LC-MS/MS and its application to a toxicokinetics study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22622066/),[ml] / [min],0.6,146129,DB00542,Benazepril
,22622066,gradient flow rates,"The mobile phase was composed of 0.1% acetic acid-acetonitrile (50:50, v/v), with gradient flow rates: 0.6 mL/min (0-4.55 min); 4.55-4.65 min, 1 mL/min; 1 mL/min (4.65-9.5 min); 9.5-9.6 min, 0.6 mL/min; 0.6 mL/min (9.6-10 min).","Simultaneous determination of lercanidipine, benazepril and benazeprilat in plasma by LC-MS/MS and its application to a toxicokinetics study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22622066/),[ml] / [min],1,146130,DB00542,Benazepril
,22622066,gradient flow rates,"The mobile phase was composed of 0.1% acetic acid-acetonitrile (50:50, v/v), with gradient flow rates: 0.6 mL/min (0-4.55 min); 4.55-4.65 min, 1 mL/min; 1 mL/min (4.65-9.5 min); 9.5-9.6 min, 0.6 mL/min; 0.6 mL/min (9.6-10 min).","Simultaneous determination of lercanidipine, benazepril and benazeprilat in plasma by LC-MS/MS and its application to a toxicokinetics study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22622066/),[ml] / [min],1,146131,DB00542,Benazepril
,22622066,gradient flow rates,"The mobile phase was composed of 0.1% acetic acid-acetonitrile (50:50, v/v), with gradient flow rates: 0.6 mL/min (0-4.55 min); 4.55-4.65 min, 1 mL/min; 1 mL/min (4.65-9.5 min); 9.5-9.6 min, 0.6 mL/min; 0.6 mL/min (9.6-10 min).","Simultaneous determination of lercanidipine, benazepril and benazeprilat in plasma by LC-MS/MS and its application to a toxicokinetics study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22622066/),min,9.5-9.6,146132,DB00542,Benazepril
,22622066,gradient flow rates,"The mobile phase was composed of 0.1% acetic acid-acetonitrile (50:50, v/v), with gradient flow rates: 0.6 mL/min (0-4.55 min); 4.55-4.65 min, 1 mL/min; 1 mL/min (4.65-9.5 min); 9.5-9.6 min, 0.6 mL/min; 0.6 mL/min (9.6-10 min).","Simultaneous determination of lercanidipine, benazepril and benazeprilat in plasma by LC-MS/MS and its application to a toxicokinetics study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22622066/),[ml] / [min],0.6,146133,DB00542,Benazepril
,22622066,gradient flow rates,"The mobile phase was composed of 0.1% acetic acid-acetonitrile (50:50, v/v), with gradient flow rates: 0.6 mL/min (0-4.55 min); 4.55-4.65 min, 1 mL/min; 1 mL/min (4.65-9.5 min); 9.5-9.6 min, 0.6 mL/min; 0.6 mL/min (9.6-10 min).","Simultaneous determination of lercanidipine, benazepril and benazeprilat in plasma by LC-MS/MS and its application to a toxicokinetics study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22622066/),[ml] / [min],0.6,146134,DB00542,Benazepril
,2344861,"time to maximum plasma concentration,","The time to maximum plasma concentration, tmax (0.5 h) and elimination half-life (0.6 h) in the elderly were the same as in young subjects.",Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2344861/),h,0.5,190544,DB00542,Benazepril
,2344861,tmax,"The time to maximum plasma concentration, tmax (0.5 h) and elimination half-life (0.6 h) in the elderly were the same as in young subjects.",Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2344861/),h,0.5,190545,DB00542,Benazepril
,2344861,elimination half-life,"The time to maximum plasma concentration, tmax (0.5 h) and elimination half-life (0.6 h) in the elderly were the same as in young subjects.",Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2344861/),h,0.6,190546,DB00542,Benazepril
,2344861,tmax,"The kinetics of benazeprilat was slightly changed in the elderly; although its tmax (1.5 h) was not affected, Cmax and the AUC were 20-40% greater.",Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2344861/),h,1.5,190547,DB00542,Benazepril
,2344861,renal plasma clearance,The renal plasma clearance of benazeprilat (18.1 ml.min-1) was about 20% smaller than in the young subjects.,Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2344861/),[ml] / [min],18.1,190548,DB00542,Benazepril
,10052059,area under the curve (AUC),The area under the curve (AUC) for enalaprilat increased after surgery from 23.6 +/- 14.7 to 42.4 +/- 20.9 micrograms.minute/mL (P < .01).,"Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052059/),[min·μg] / [ml],23.6,207016,DB00542,Benazepril
,10052059,area under the curve (AUC),The area under the curve (AUC) for enalaprilat increased after surgery from 23.6 +/- 14.7 to 42.4 +/- 20.9 micrograms.minute/mL (P < .01).,"Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052059/),[min·μg] / [ml],42.4,207017,DB00542,Benazepril
,10052059,peak plasma concentration (Cmax),"Mean peak plasma concentration (Cmax) was increased in the impaired dogs (59.1 +/- 23.3 versus 43.9 +/- 32.9 ng/mL), but this variation was not significant (P > .05).","Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052059/),[ng] / [ml],59.1,207018,DB00542,Benazepril
,10052059,peak plasma concentration (Cmax),"Mean peak plasma concentration (Cmax) was increased in the impaired dogs (59.1 +/- 23.3 versus 43.9 +/- 32.9 ng/mL), but this variation was not significant (P > .05).","Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052059/),[ng] / [ml],43.9,207019,DB00542,Benazepril
,10052059,AUC,"Renal failure had no significant effect on AUC for benazeprilat (13.8 +/- 9.8 versus 14.9 +/- 5.0 micrograms.minute/mL) (P > .05), but Cmax decreased significantly (from 55.0 +/- 26.4 to 31.9 +/- 17.7 ng/mL) (P < .05).","Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052059/),[min·μg] / [ml],13.8,207020,DB00542,Benazepril
,10052059,AUC,"Renal failure had no significant effect on AUC for benazeprilat (13.8 +/- 9.8 versus 14.9 +/- 5.0 micrograms.minute/mL) (P > .05), but Cmax decreased significantly (from 55.0 +/- 26.4 to 31.9 +/- 17.7 ng/mL) (P < .05).","Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052059/),[min·μg] / [ml],14.9,207021,DB00542,Benazepril
,10052059,Cmax,"Renal failure had no significant effect on AUC for benazeprilat (13.8 +/- 9.8 versus 14.9 +/- 5.0 micrograms.minute/mL) (P > .05), but Cmax decreased significantly (from 55.0 +/- 26.4 to 31.9 +/- 17.7 ng/mL) (P < .05).","Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052059/),[ng] / [ml],55.0,207022,DB00542,Benazepril
,10052059,Cmax,"Renal failure had no significant effect on AUC for benazeprilat (13.8 +/- 9.8 versus 14.9 +/- 5.0 micrograms.minute/mL) (P > .05), but Cmax decreased significantly (from 55.0 +/- 26.4 to 31.9 +/- 17.7 ng/mL) (P < .05).","Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10052059/),[ng] / [ml],31.9,207023,DB00542,Benazepril
,8599524,elimination of half-life,"The elimination of half-life of benazeprilat was 3.5 hours, although an additional terminal phase was observed in some dogs.","Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599524/),h,3.5,214353,DB00542,Benazepril
,8599524,half-life for accumulation,The effective half-life for accumulation for all 4 dosages was 12 hours.,"Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599524/),h,12,214354,DB00542,Benazepril
,8599524,time to peak effect,"All dosages of benazepril caused profound inhibition of ACE, with rapid onset of activity (time to peak effect, 2 hours) and long duration of action (single administration of all 4 doses induced inhibition of ACE that was significantly different from the value in the control [vehicle-treated] dogs for all time points between 1 and 30 hours).","Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599524/),h,2,214355,DB00542,Benazepril
,10688627,half-life of,The half-life of benazeprilat elimination determined from this physiologically based model was 39 +/- 6 min.,Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688627/),min,39,214485,DB00542,Benazepril
,10688627,maximal binding capacity,"The estimated maximal binding capacity of benazeprilat to ACE was approximately 23.5 nmol/kg, 90% of which was tissular.",Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688627/),[nM] / [kg],23.5,214486,DB00542,Benazepril
,10688627,equilibrium constant of dissociation (K(d)),The estimated equilibrium constant of dissociation (K(d)) of benazeprilat to ACE was 2.7 to 4.5 nM.,Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688627/),nM,2.7 to 4.5,214487,DB00542,Benazepril
,10688627,K(d),"IC(50) values were one order of magnitude lower than K(d) values (i.e., approximately 0.27 nM).",Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688627/),nM,0.27,214488,DB00542,Benazepril
,12755906,Vc,Benazeprilat data were fitted to an equation corresponding to a single-compartment model with a volume equal to the blood space (Vc = 0.093 L/kg).,Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12755906/),[l] / [kg],0.093,214729,DB00542,Benazepril
,12755906,t1/2,"Free benazeprilat was eliminated quickly from the central compartment (t1/2 approximately 1.0 h; Cl approximately 0.125 L/kg/h), elimination being principally biliary ( approximately 85%) rather than urinary ( approximately 15%).",Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12755906/),h,1.0,214730,DB00542,Benazepril
,12755906,Cl,"Free benazeprilat was eliminated quickly from the central compartment (t1/2 approximately 1.0 h; Cl approximately 0.125 L/kg/h), elimination being principally biliary ( approximately 85%) rather than urinary ( approximately 15%).",Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12755906/),[l] / [h·kg],0.125,214731,DB00542,Benazepril
,12755906,t1/2,"Nevertheless, inhibition of ACE was long-lasting (t1/2 16-23 h) due to high affinity binding of benazeprilat to ACE (Kd approximately 3.5 mmol/L, IC50 approximately 4.3 mmol/L).",Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12755906/),h,16-23,214732,DB00542,Benazepril
,12755906,Kd,"Nevertheless, inhibition of ACE was long-lasting (t1/2 16-23 h) due to high affinity binding of benazeprilat to ACE (Kd approximately 3.5 mmol/L, IC50 approximately 4.3 mmol/L).",Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12755906/),[mM] / [l],3.5,214733,DB00542,Benazepril
,12755906,IC50,"Nevertheless, inhibition of ACE was long-lasting (t1/2 16-23 h) due to high affinity binding of benazeprilat to ACE (Kd approximately 3.5 mmol/L, IC50 approximately 4.3 mmol/L).",Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12755906/),[mM] / [l],4.3,214734,DB00542,Benazepril
,2058180,peak plasma concentration,"The peak plasma concentration of benazepril (0.58 +/- 0.13 nmol/g (SD] was observed at 0.5h after dose, indicating rapid absorption.",The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058180/),[nM] / [g],0.58,218763,DB00542,Benazepril
,2058180,Peak concentrations,"Peak concentrations of radioactivity (1.88 +/- 0.48 nmol/g) and of active benazeprilat (0.84 +/- 0.25 nmol/g) were observed at 1 h after dose, demonstrating rapid bioactivation.",The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058180/),[nM] / [g],1.88,218764,DB00542,Benazepril
,2058180,Peak concentrations,"Peak concentrations of radioactivity (1.88 +/- 0.48 nmol/g) and of active benazeprilat (0.84 +/- 0.25 nmol/g) were observed at 1 h after dose, demonstrating rapid bioactivation.",The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058180/),[nM] / [g],0.84,218765,DB00542,Benazepril
,2058180,area under the plasma curve (AUC0-96 h),"3. The area under the plasma curve (AUC0-96 h) of total radioactivity amounted to 9.7 +/- 1.1 (nmol/g)h, 5% of which was accounted for by benazepril and about 50% by benazeprilat.",The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058180/),h,9.7,218766,DB00542,Benazepril
,2203579,Absorption,"Absorption of the active diacids is generally poor, and moderate (typically 30 to 70%) for the prodrugs.",Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),%,30 to 70,223514,DB00542,Benazepril
,2203579,bioavailability,The bioavailability of lisinopril is about 25%.,Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),%,25,223515,DB00542,Benazepril
,2203579,Half-lives of accumulation,Half-lives of accumulation are of the order of 12 hours; protein binding varies from little (lisinopril) to 90% (benazeprilat).,Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),h,12,223516,DB00542,Benazepril
,2203579,protein binding,Half-lives of accumulation are of the order of 12 hours; protein binding varies from little (lisinopril) to 90% (benazeprilat).,Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),%,90,223517,DB00542,Benazepril
,22122818,maximum plasma concentration (C(max)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[ng] / [ml],168,247743,DB00542,Benazepril
,22122818,maximum plasma concentration (C(max)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[ng] / [ml],121,247744,DB00542,Benazepril
,22122818,maximum plasma concentration (C(max)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[ng] / [ml],418,247745,DB00542,Benazepril
,22122818,exposure (AUC(0-48 h)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[h·ng] / [ml],"1,160",247746,DB00542,Benazepril
,22122818,exposure (AUC(0-48 h)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[h·ng] / [ml],955,247747,DB00542,Benazepril
,22122818,exposure (AUC(0-48 h)),"Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively.",Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122818/),[h·ng] / [ml],"2,801",247748,DB00542,Benazepril
,2758102,tmax,HCl was rapidly absorbed (tmax = 0.5 h) and rapidly eliminated from plasma (t1/2 = 0.6 h).,Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril. HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758102/),h,0.5,258897,DB00542,Benazepril
,2758102,t1/2,HCl was rapidly absorbed (tmax = 0.5 h) and rapidly eliminated from plasma (t1/2 = 0.6 h).,Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril. HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758102/),h,0.6,258898,DB00542,Benazepril
,2758102,tmax,The drug was rapidly metabolized to benazeprilat (tmax = 1.5 h).,Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril. HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758102/),h,1.5,258899,DB00542,Benazepril
,2758102,t 1/2,"About 80 per cent of benazeprilat formed was eliminated within 24 h (t 1/2 = 2.7 h), whereas the terminal phase (t1/2 = 22.3 h) controlled a minor amount of elimination.",Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril. HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758102/),h,2.7,258900,DB00542,Benazepril
,2758102,terminal phase (t1/2,"About 80 per cent of benazeprilat formed was eliminated within 24 h (t 1/2 = 2.7 h), whereas the terminal phase (t1/2 = 22.3 h) controlled a minor amount of elimination.",Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril. HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758102/),h,22.3,258901,DB00542,Benazepril
,2758102,accumulation ratio,The accumulation ratio was 1.20 for AUC and 1.24 for urinary excretion.,Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril. HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758102/),,1.20,258902,DB00542,Benazepril
,2758102,accumulation ratio,The accumulation ratio was 1.20 for AUC and 1.24 for urinary excretion.,Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril. HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758102/),,1.24,258903,DB00542,Benazepril
,2758102,effective half-life for accumulation,The effective half-life for accumulation was estimated at about 10-11 h.,Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril. HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758102/),h,10-11,258904,DB00542,Benazepril
,24739274,flow rate,Applying a mobile phase gradient of acidified methanol and acidified water at a flow rate of 0.4ml/min the column effluent was monitored during a total run time of 7.5min by tandem mass spectrometry with electrospray ionization.,Liquid chromatography-tandem mass spectrometry method for determination of aliskiren in saliva and its application to a clinical trial with healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24739274/),[ml] / [min],0.4,271786,DB00542,Benazepril
,24739274,total run time,Applying a mobile phase gradient of acidified methanol and acidified water at a flow rate of 0.4ml/min the column effluent was monitored during a total run time of 7.5min by tandem mass spectrometry with electrospray ionization.,Liquid chromatography-tandem mass spectrometry method for determination of aliskiren in saliva and its application to a clinical trial with healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24739274/),min,7.5,271787,DB00542,Benazepril
